Altmetric

Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)

File Description SizeFormat 
s12879-023-08292-y.pdfPublished version1.62 MBAdobe PDFView/Open
Title: Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)
Authors: Da Silva Duarte, G
Jones, AD
De Goes Cavalcanti, LP
De Melo Rêgo, MJB
Ribeiro, GS
Boyton, RJ
Pereira, DB
Croda, JHR
Costa, FTM
Duarte, AP
Consolaro, MEL
Stabeli, RG
Negrão, FJ
Proenca-Modena, JL
Villalobos-Salcedo, JM
Da Rocha Castelar Pinheiro, G
De Barros Albuquerque, AP
De Almeida Barreto, FK
Moreira, J
Ferrari, IC
Évora, PM
Da Silva, VRS
Lacerda, MVG
Altmann, DM
REPLICK network
Siqueira, AM
Item Type: Journal Article
Abstract: BACKGROUND: Chikungunya is associated with high morbidity and the natural history of symptomatic infection has been divided into three phases (acute, post-acute, and chronic) according to the duration of musculoskeletal symptoms. Although this classification has been designed to help guide therapeutic decisions, it does not encompass the complexity of the clinical expression of the disease and does not assist in the evaluation of the prognosis of severity nor chronic disease. Thus, the current challenge is to identify and diagnose musculoskeletal disorders and to provide the optimal treatment in order to prevent perpetuation or progression to a potentially destructive disease course. METHODS: The study is the first product of the Clinical and Applied Research Network in Chikungunya (REPLICK). This is a prospective, outpatient department-based, multicenter cohort study in Brazil. Four work packages were defined: i. Clinical research; ii) Translational Science - comprising immunology and virology streams; iii) Epidemiology and Economics; iv) Therapeutic Response and clinical trials design. Scheduled appointments on days 21 (D21) ± 7 after enrollment, D90 ± 15, D120 ± 30, D180 ± 30; D360 ± 30; D720 ± 60, and D1080 ± 60 days. On these visits a panel of blood tests are collected in addition to the clinical report forms to obtain data on socio-demographic, medical history, physical examination and questionnaires devoted to the evaluation of musculoskeletal manifestations and overall health are performed. Participants are asked to consent for their specimens to be maintained in a biobank. Aliquots of blood, serum, saliva, PAXgene, and when clinically indicated to be examined, synovial fluid, are stored at -80° C. The study protocol was submitted and approved to the National IRB and local IRB at each study site. DISCUSSION: Standardized and harmonized patient cohorts are needed to provide better estimates of chronic arthralgia development, the clinical spectra of acute and chronic disease and investigation of associated risk factors. This study is the largest evaluation of the long-term sequelae of individuals infected with CHIKV in the Brazilian population focusing on musculoskeletal manifestations, mental health, quality of life, and chronic pain. This information will both define disease burden and costs associated with CHIKV infection, and better inform therapeutic guidelines.
Issue Date: 28-Jul-2023
Date of Acceptance: 28-Apr-2023
URI: http://hdl.handle.net/10044/1/105859
DOI: 10.1186/s12879-023-08292-y
ISSN: 1471-2334
Publisher: BMC
Start Page: 1
End Page: 12
Journal / Book Title: BMC Infectious Diseases
Volume: 23
Copyright Statement: © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publication Status: Published
Conference Place: England
Article Number: 499
Online Publication Date: 2023-07-28
Appears in Collections:Department of Infectious Diseases



This item is licensed under a Creative Commons License Creative Commons